Page last updated: 2024-10-26

stallimycin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

stallimycin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lee, M1
Roldan, MC1
Haskell, MK1
McAdam, SR1
Hartley, JA1

Other Studies

1 other study available for stallimycin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
    Journal of medicinal chemistry, 1994, Apr-15, Volume: 37, Issue:8

    Topics: Alkylation; Antineoplastic Agents; Base Composition; Coumarins; Cross-Linking Reagents; DNA; Ficusin

1994